A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer

@article{Sunela2009APS,
  title={A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer},
  author={Kaisa Leea Sunela and Sanna K. Koskinen and Pirkko-Liisa Irmeli Kellokumpu-Lehtinen},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2009},
  volume={66},
  pages={59-67}
}
Combination of capecitabine and interferon has shown activity in metastatic renal cell carcinoma. Pegylated interferons might have more clinical activity and fewer side effects. This study evaluated the efficacy, tolerability, and safety of the combination of capecitabine and pegylated interferon alfa-2a. In this open label, single institution, non-randomized phase-II first-line study, 26 patients were included. Capecitabine was administered 2,000 mg/m2 daily for 14 days followed by 1 week rest… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 36 references

NCCN Kidney Cancer Panel members . NCCN clinical practice guidelines in oncology . Kidney Cancer V . I .

  • RS Motzer, RA Figlin, T Olencki
  • 2010

NCCN Kidney Cancer Panel members. NCCN clinical practice guidelines in oncology. Kidney Cancer V.I.2010

  • RS Motzer, RA Figlin, T Olencki
  • htpp://www.nccn.org
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…